Substitutioner observeret i kliniske isolater (rtT184A, C, F, G, I, L, M eller S; rtS202 C, G eller I; og/ eller rtM250I, L eller V) reducerede yderligere entecavirfølsomheden 16 til 741 gange i forhold til vild- type virus.
Substitutions observed in clinical isolates (rtT184A, C, F, G, I, L, M or S; rtS202 C, G or I; and/ or rtM250I, L or V) further decreased entecavir susceptibility 16- to 741-fold relative to wild-type virus.